ABSTRACT
The bladder is continuously protected by passive defences such as a mucus layer, antimicrobial peptides and secretory immunoglobulins; however, these defences are occasionally overcome by invading bacteria that can induce a strong host inflammatory response in the bladder. The urothelium and resident immune cells produce additional defence molecules, cytokines and chemokines, which recruit inflammatory cells to the infected tissue. Resident and recruited immune cells act together to eradicate bacteria from the bladder and to develop lasting immune memory against infection. However, urinary tract infection (UTI) is commonly recurrent, suggesting that the induction of a memory response in the bladder is inadequate to prevent reinfection. Additionally, infection seems to induce long-lasting changes in the urothelium, which can render the tissue more susceptible to future infection. The innate immune response is well-studied in the field of UTI, but considerably less is known about how adaptive immunity develops and how repair mechanisms restore bladder homeostasis following infection. Furthermore, data demonstrate that sex-based differences in immunity affect resolution and infection can lead to tissue remodelling in the bladder following resolution of UTI. To combat the rise in antimicrobial resistance, innovative therapeutic approaches to bladder infection are currently in development. Improving our understanding of how the bladder responds to infection will support the development of improved treatments for UTI, particularly for those at risk of recurrent infection.
Subject(s)
Urinary Bladder Diseases/immunology , Urinary Bladder Diseases/microbiology , Urinary Bladder/immunology , Urinary Tract Infections/immunology , HumansABSTRACT
Immunoglobulin G4-related disease (IgG4-RD) is a recently described inflammatory disease with multiorgan involvement. Although there were reports of IgG4-related kidney disease or prostatitis, this disease rarely presents in the bladder. In this report, we describe a case of IgG4-RD arising from bladder wall. This patient had a past history of autoimmune pancreatitis and presented with incidental bladder tumor. Magnetic resonance imaging showed low signal intensity tumor on T2-weighted image, and no invasion to the muscular layer. We performed transurethral resection. Pathological findings showed that there were chronic inflammatory changes infiltrates under the epithelium, and IgG4-positive plasma cells were scattered throughout the lesion. They met the pathological diagnostic criteria for IgG4-RD. We think this is the first case of IgG4-RD arising from and confined to the inside of the bladder wall.
Subject(s)
Immunoglobulin G4-Related Disease/diagnosis , Urinary Bladder Diseases/diagnosis , Urinary Bladder Diseases/immunology , Aged , Humans , MaleSubject(s)
Chronic Pain/therapy , Cystitis, Interstitial/therapy , Pelvic Pain/therapy , Urinary Bladder/pathology , Chronic Pain/diagnosis , Chronic Pain/immunology , Cyclohexanols/therapeutic use , Cystitis, Interstitial/diagnosis , Cystitis, Interstitial/immunology , Humans , Indans/therapeutic use , Pelvic Pain/diagnosis , Pelvic Pain/immunology , Urinary Bladder/immunology , Urinary Bladder Diseases/diagnosis , Urinary Bladder Diseases/immunology , Urinary Bladder Diseases/therapyABSTRACT
Immunoglobulin G4-related disease is a fibroinflammatory condition of unclear etiology that can present with inflammatory changes and enlargement of a wide variety of organs, most commonly in the gastrointestinal tract. A diagnosis requires an elevated serum immunoglobulin G4 concentration and a tissue biopsy showing a dense plasma cell infiltrate with an increased percentage of immunoglobulin G4+ plasma cells. This disease infrequently presents in the genitourinary tract, and as such might be unfamiliar to and potentially overlooked by urologists. Here we present the third reported case of immunoglobulin G4-related disease manifesting as a mass in the urinary bladder.
Subject(s)
Immunoglobulin G/blood , Urinary Bladder Diseases/diagnosis , Urinary Bladder Diseases/immunology , Urinary Bladder/pathology , Aged , Female , Fibrosis , Humans , Immunoglobulin G/analysis , Immunologic Factors/therapeutic use , Inflammation/blood , Inflammation/pathology , Plasma Cells/chemistry , Rituximab/therapeutic useABSTRACT
Inhibiting antibodies targeting receptor-binding pockets in proteins is a major focus in the development of vaccines and in antibody-based therapeutic strategies. Here, by using a common mannose-specific fimbrial adhesin of Escherichia coli, FimH, we demonstrate that locking the adhesin in a low-binding conformation induces the production of binding pocket-specific, adhesion-inhibiting antibodies. A di-sulfide bridge was introduced into the conformationally dynamic FimH lectin domain, away from the mannose-binding pocket but rendering it defective with regard to mannose binding. Unlike the native, functionally active lectin domain, the functionally defective domain was potent in inducing inhibitory monoclonal antibodies that blocked FimH-mediated bacterial adhesion to epithelial cells and urinary bladder infection in mice. Inhibition of adhesion involved direct competition between the antibodies and mannose for the binding pocket. Binding pocket-specific inhibitory antibodies also were abundant in polyclonal immune serum raised against the functionally defective lectin domain. The monoclonal antibodies elicited against the binding-defective protein bound to the high-affinity conformation of the adhesin more avidly than to the low-affinity form. However, both soluble mannose and blood plasma more strongly inhibited antibody recognition of the high-affinity FimH conformation than the low-affinity form. We propose that in the functionally active conformation the binding-pocket epitopes are shielded from targeted antibody development by ligand masking and that strong immunogenicity of the binding pocket is unblocked when the adhesive domain is in the nonbinding conformation.
Subject(s)
Adhesins, Escherichia coli/chemistry , Antibodies, Monoclonal/immunology , Binding Sites, Antibody/immunology , Escherichia coli/metabolism , Fimbriae Proteins/chemistry , Models, Molecular , Protein Conformation , Urinary Bladder Diseases/microbiology , Adhesins, Escherichia coli/genetics , Animals , Bacterial Adhesion/immunology , Escherichia coli/genetics , Fimbriae Proteins/genetics , Mannose/metabolism , Mice , Mutation, Missense/genetics , Protein Binding , Urinary Bladder Diseases/immunologyABSTRACT
A previously healthy 72-year old woman was admitted with a chief complaint of gross hematuria and fecaluria for 4 months. On initial computed tomographic examination, a lobulated shaped intravesical protruding mass with adhesion to the sigmoid colon was identified. Under a clinical diagnosis of bladder cancer with vesicosigmoid fistula vs sigmoid colon cancer with vesicosigmoid fistula, a frozen section evaluation of the bladder mass was performed to determine the origin of the tumor. Because the frozen section diagnosis of the bladder mass was an inflammatory origin, a partial cystectomy with segmental resection of the adherent sigmoid colon was elected. The microscopic examination of the partial resection of the urinary bladder revealed suburothelial inflammatory mass lesion, involving the entire wall of bladder with extension to the sigmoid colon, which was composed of spindle cells without significant atypia admixed with many lymphocytes, plasma cells, and some scattered eosinophils. Chronic inflammation around nerve bundles, sclerotic fibrosis, and prominent lymphoid follicles with plasma cells were the main features of the mass. No urothelial dysplasia or malignancy was seen. An average of 57 plasma cells per 1 high-power field was immunoreactive for immunoglobulin (Ig) G4 with IgG4/IgG ratio of more than 40%, a diagnostic feature of IgG4-associated inflammatory pseudotumor (IPT), arising in the bladder with the secondary involvement of the sigmoid colon. Recent studies reported many IPTs associated with IgG4 in other locations; however, to the best of our knowledge, IgG4-associated IPT in the urinary bladder has not been reported. We describe herein the first case of IgG4-associated IPT, lymphoplasmacytic type in the urinary bladder.
Subject(s)
Granuloma, Plasma Cell/pathology , Immunoglobulin G/immunology , Urinary Bladder Diseases/pathology , Aged , Female , Granuloma, Plasma Cell/diagnostic imaging , Granuloma, Plasma Cell/immunology , Granuloma, Plasma Cell/surgery , Humans , Plasma Cells/immunology , Plasma Cells/pathology , Tomography, X-Ray Computed , Urinary Bladder/diagnostic imaging , Urinary Bladder/immunology , Urinary Bladder/pathology , Urinary Bladder/surgery , Urinary Bladder Diseases/diagnostic imaging , Urinary Bladder Diseases/immunology , Urinary Bladder Diseases/surgeryABSTRACT
New animal models are greatly needed in interstitial cystitis/painful bladder syndrome (IC/PBS) research. We recently developed a novel transgenic cystitis model (URO-OVA mice) that mimics certain key aspects of IC/PBS pathophysiology. This paper aimed to determine whether URO-OVA cystitis model was responsive to intravesical dimethyl sulfoxide (DMSO) and if so identify the mechanisms of DMSO action. URO-OVA mice developed acute cystitis upon adoptive transfer of OVA-specific OT-I splenocytes. Compared to PBS-treated bladders, the bladders treated with 50% DMSO exhibited markedly reduced bladder histopathology and expression of various inflammatory factor mRNAs. Intravesical DMSO treatment also effectively inhibited bladder inflammation in a spontaneous chronic cystitis model (URO-OVA/OT-I mice). Studies further revealed that DMSO could impair effector T cells in a dose-dependent manner in vitro. Taken together, our results suggest that intravesical DMSO improves the bladder histopathology of IC/PBS patients because of its ability to interfere with multiple inflammatory and bladder cell types.
Subject(s)
Autoimmune Diseases/genetics , Cystitis/genetics , Dimethyl Sulfoxide/pharmacology , Urinary Bladder Diseases/immunology , Acute Disease , Animals , Chronic Disease , Disease Models, Animal , Dose-Response Relationship, Drug , Epitopes , Female , Inflammation , Mice , Mice, Transgenic , Spleen/cytologyABSTRACT
Traumatic spinal cord injury (SCI) permanently alters bladder function in humans. Hematuria and cystitis occur in both human SCI as well as in rodent models of SCI. Others have reported early SCI-dependent disruption to bladder uroepithelial integrity that results in increased permeability to urine and urine-borne substances. This can result in cystitis, or inflammation of the bladder, an ongoing pathological condition present throughout the chronic phase of SCI in humans. The goals of our study were twofold: (1) to begin to examine the inflammatory and molecular changes that occur within the bladder uroepithelium using a clinically-relevant spinal contusion model of injury, and (2) to assess whether these alterations continue into the chronic phase of SCI. Rats received either moderate SCI or sham surgery. Urine was collected from SCI and sham subjects over 7 days or at 7 months to assess levels of excreted proteins. Inflammation in the bladder wall was assessed via biochemical and immunohistochemical methods. Bladder tight junction proteins, mediators of uroepithelial integrity, were also measured in both the acute and chronic phases of SCI. Urine protein and hemoglobin levels rapidly increase following SCI. An SCI-dependent elevation in numbers of neutrophils within the bladder wall peaked at 48 h. Bladder tight junction proteins demonstrate a rapid but transient decrease as early as 2 h post-SCI. Surprisingly, elevated levels of urine proteins and significant deficits in bladder tight junction proteins could be detected in chronic SCI, suggesting that early pathological changes to the bladder may continue throughout the chronic phase of injury.
Subject(s)
Spinal Cord Injuries/complications , Urinary Bladder Diseases/etiology , Urinary Bladder Diseases/pathology , Urinary Bladder/pathology , Animals , Blotting, Western , Chronic Disease , Female , Hematuria/etiology , Immunohistochemistry , Neutrophil Infiltration , Proteinuria/etiology , Rats , Rats, Sprague-Dawley , Urinary Bladder/innervation , Urinary Bladder Diseases/immunologyABSTRACT
Components of bacteria have been shown to induce innate antiviral immunity via Toll-like receptors (TLRs). We have recently shown that FimH, the adhesin portion of type 1 fimbria, can induce the innate immune system via TLR4. Here we report that FimH induces potent in vitro and in vivo innate antimicrobial responses. FimH induced an innate antiviral state in murine macrophage and primary MEFs which was correlated with IFN-beta production. Moreover, FimH induced the innate antiviral responses in cells from wild type, but not from MyD88(-/-), Trif(-/-), IFN-alpha/betaR(-/-) or IRF3(-/-) mice. Vaginal delivery of FimH, but not LPS, completely protected wild type, but not MyD88(-/-), IFN-alpha/betaR(-/-), IRF3(-/-) or TLR4(-/-) mice from subsequent genital HSV-2 challenge. The FimH-induced innate antiviral immunity correlated with the production of IFN-beta, but not IFN-alpha or IFN-gamma. To examine whether FimH plays a role in innate immune induction in the context of a natural infection, the innate immune responses to wild type uropathogenic E. coli (UPEC) and a FimH null mutant were examined in the urinary tract of C57Bl/6 (B6) mice and TLR4-deficient mice. While UPEC expressing FimH induced a robust polymorphonuclear response in B6, but not TLR4(-/-) mice, mutant bacteria lacking FimH did not. In addition, the presence of TLR4 was essential for innate control of and protection against UPEC. Our results demonstrate that FimH is a potent inducer of innate antimicrobial responses and signals differently, from that of LPS, via TLR4 at mucosal surfaces. Our studies suggest that FimH can potentially be used as an innate microbicide against mucosal pathogens.
Subject(s)
Adhesins, Escherichia coli/immunology , Fimbriae Proteins/immunology , Immunity, Innate , Interferon Type I/metabolism , Signal Transduction , Toll-Like Receptor 4/metabolism , Adhesins, Escherichia coli/metabolism , Animals , Cell Line , Cells, Cultured , Colony Count, Microbial , Escherichia coli/growth & development , Escherichia coli/pathogenicity , Escherichia coli Infections/immunology , Escherichia coli Infections/microbiology , Female , Fimbriae Proteins/metabolism , Herpes Genitalis/immunology , Herpes Genitalis/metabolism , Herpes Genitalis/virology , Herpesvirus 2, Human/immunology , Herpesvirus 2, Human/physiology , Humans , Interferon Type I/immunology , Lipopolysaccharides/immunology , Macrophages/immunology , Macrophages/virology , Mice , Myeloid Differentiation Factor 88/immunology , Myeloid Differentiation Factor 88/metabolism , Toll-Like Receptor 4/immunology , Urinary Bladder Diseases/immunology , Urinary Bladder Diseases/microbiology , Urinary Tract Infections/immunology , Urinary Tract Infections/microbiology , Vagina/pathologyABSTRACT
OBJECTIVES: Botulinum toxin type A (BoNT/A) proved very effective in therapy for hyperactive detrusor or sphincter dysfunction of neurogenic and non-neurogenic origin. However, therapy may fail. In a search for possible reasons, we investigated the presence of BoNT/A antibodies (BoNT/A-AB) in patients who were treated more than once and correlated the presence of antibodies with clinical findings. METHODS: In 25 patients (aged 11-75 years; average, 48.3 years) who had experienced at least one previous BoNT/A detrusor and/or sphincter injection, BoNT/A-AB was detected with the mouse diaphragm assay before and within 3 months after the current injection. Clinically, subjective and objective outcomes of this injection session were determined on an efficacy scale. RESULTS: In eight patients, BoNT/A-AB was detected; titers were clearly positive in four patients and were borderline in four patients. The subjective and objective outcomes indicated complete therapy failure in three of four patients who were positive for BoNT/A-AB. In two patients, BoNT/A-AB developed after just one injection session. CONCLUSIONS: Botulinum toxin type A antibodies can develop after injection of BoNT/A for urologic disorders and the antibodies can lead to therapy failure. In patients with clinically complete therapy failure in whom no obvious other causes can be determined (such as a progressive disease in a patient with multiple sclerosis), screening for BoNT/A-AB should be carried out.
Subject(s)
Antibodies/immunology , Botulinum Toxins, Type A/immunology , Botulinum Toxins, Type A/therapeutic use , Urinary Bladder Diseases/drug therapy , Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , Treatment Failure , Urinary Bladder Diseases/immunology , Urinary Incontinence/drug therapy , Urinary Incontinence/immunologyABSTRACT
Physiological techniques can be used to detect novel autoantibodies causing alteration of autonomic function after passive transfer to mice. Previously, such antibodies have been detected in patients with type I diabetes mellitus, myasthenia gravis, and Sjogren's syndrome. We now describe a patient with an idiopathic nondiabetic neuropathy with prominent autonomic symptoms, including bladder and bowel dysfunction. Physiological assays of whole colon and bladder were used to determine the presence in the patient serum of functional autoantibodies capable of mediating autonomic dysfunction. Immunoglobulin G (IgG) from this patient was able to disrupt bladder and bowel function on passive transfer to mice. This is a new pattern of autoantibody-mediated abnormality. Although the target antigen is unknown, it is likely to be a cell-surface receptor or ion channel. This case highlights the usefulness of passive transfer studies in detecting functional antibodies in patients with autonomic neuropathy.
Subject(s)
Autoimmune Diseases of the Nervous System/immunology , Autonomic Nervous System Diseases/immunology , Colonic Diseases/immunology , Muscle Hypertonia/immunology , Urinary Bladder Diseases/immunology , Aged , Animals , Autoantibodies/blood , Autoimmune Diseases of the Nervous System/physiopathology , Autonomic Nervous System Diseases/physiopathology , Chronic Disease , Colonic Diseases/physiopathology , Cystoscopy , Female , Humans , Immunization, Passive , Immunoglobulin G/blood , Male , Mice , Mice, Inbred BALB C , Muscle Hypertonia/physiopathology , Myoelectric Complex, Migrating/physiology , Urinary Bladder Diseases/physiopathologyABSTRACT
The initial treatment of bladder cancer is transurethral resection (TUR), but this cancer recurs at an important rate, and has 14% chance of progression after TUR alone. Intravesical chemotherapy with Bacillus Calmette-Guerin (BCG) is effective against recurrence and progression of bladder cancer. However, this therapeutic expose to many local and systemic side-effects. We report a case of 63-year-old man who presented bladder tuberculosis after a BCG therapy, which required 6 months of antitubercular therapy.
Subject(s)
BCG Vaccine/therapeutic use , Tuberculosis/immunology , Urinary Bladder Diseases/immunology , Urinary Bladder Diseases/microbiology , Administration, Intravesical , BCG Vaccine/administration & dosage , Humans , Male , Middle Aged , Treatment OutcomeABSTRACT
The role of dendritic cells (DC) in urinary tract infections (UTI) is unknown. These cells contribute directly to the innate defense against various viral and bacterial infections. Here, we studied their role in UTI using an experimental model induced by transurethral instillation of the uropathogenic Escherichia coli (UPEC) strain 536 into C57BL/6 mice. While few DC were found in the uninfected bladder, many had been recruited after 24 h, mostly to the submucosa and uroepithelium. They expressed markers of activation and maturation and exhibited the CD11b+ F4/80+ CD8- Gr-1- myeloid subtype. Also, tumor necrosis factor alpha (TNF-alpha)- and inducible nitric oxide synthase (iNOS)-producing CD11bINT DC (Tip-DC) were detected, which recently were proposed to be critical in the defense against bacterial infections. However, Tip-DC-deficient CCR2-/- mice did not show reduced clearance of UPEC from the infected bladder. Moreover, clearance was also unimpaired in CD11c-DTR mice depleted of all DC by injection of diphtheria toxin. This may be explained by the abundance of granulocytes and of iNOS- and TNF-alpha-producing non-DC that were able to replace Tip-DC functionality. These findings demonstrate that some of the abundant DC recruited in UTI contributed innate immune effector functions, which were, however, dispensable in the microenvironment of the bladder.
Subject(s)
Cell Movement/immunology , Dendritic Cells/enzymology , Dendritic Cells/immunology , Escherichia coli Infections/microbiology , Nitric Oxide Synthase Type II/physiology , Tumor Necrosis Factor-alpha/physiology , Urinary Bladder Diseases/microbiology , Animals , Dendritic Cells/microbiology , Disease Models, Animal , Escherichia coli Infections/enzymology , Escherichia coli Infections/immunology , Immunity, Cellular , Mice , Mice, Inbred C57BL , Mice, Knockout , Nitric Oxide Synthase Type II/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesis , Urinary Bladder Diseases/enzymology , Urinary Bladder Diseases/immunologySubject(s)
Adhesins, Bacterial , Antigens, Bacterial , Biofilms , Escherichia coli Infections/microbiology , Escherichia coli Proteins , Escherichia coli/pathogenicity , Urinary Bladder Diseases/microbiology , Urinary Bladder/microbiology , Urinary Tract Infections/microbiology , Adhesins, Escherichia coli , Animals , Bacterial Outer Membrane Proteins/biosynthesis , Epithelial Cells/microbiology , Epithelial Cells/ultrastructure , Escherichia coli/growth & development , Escherichia coli/immunology , Escherichia coli/ultrastructure , Escherichia coli Infections/immunology , Escherichia coli Infections/pathology , Female , Fimbriae, Bacterial/ultrastructure , Humans , Mice , Urinary Bladder/cytology , Urinary Bladder/immunology , Urinary Bladder/ultrastructure , Urinary Bladder Diseases/immunology , Urinary Bladder Diseases/pathology , Urinary Tract Infections/immunology , Urinary Tract Infections/pathology , Urothelium/microbiology , Urothelium/ultrastructureABSTRACT
Escherichia coli entry into the bladder is met with potent innate defenses, including neutrophil influx and epithelial exfoliation. Bacterial subversion of innate responses involves invasion into bladder superficial cells. We discovered that the intracellular bacteria matured into biofilms, creating pod-like bulges on the bladder surface. Pods contained bacteria encased in a polysaccharide-rich matrix surrounded by a protective shell of uroplakin. Within the biofilm, bacterial structures interacted extensively with the surrounding matrix, and biofilm associated factors had regional variation in expression. The discovery of intracellular biofilm-like pods explains how bladder infections can persist in the face of robust host defenses.
Subject(s)
Adhesins, Bacterial , Antigens, Bacterial , Biofilms , Escherichia coli Infections/microbiology , Escherichia coli Proteins , Escherichia coli/pathogenicity , Urinary Bladder Diseases/microbiology , Urinary Bladder/microbiology , Urinary Tract Infections/microbiology , Adhesins, Escherichia coli , Animals , Bacterial Outer Membrane Proteins/analysis , Colony Count, Microbial , Epithelial Cells/microbiology , Epithelial Cells/ultrastructure , Escherichia coli/growth & development , Escherichia coli/immunology , Escherichia coli/ultrastructure , Escherichia coli Infections/immunology , Escherichia coli Infections/pathology , Female , Fimbriae, Bacterial/physiology , Fimbriae, Bacterial/ultrastructure , Freeze Fracturing , Immunity, Innate , Membrane Glycoproteins/analysis , Mice , Mice, Inbred C3H , Microscopy, Electron , Microscopy, Electron, Scanning , Polysaccharides, Bacterial/analysis , Urinary Bladder/immunology , Urinary Bladder/ultrastructure , Urinary Bladder Diseases/immunology , Urinary Bladder Diseases/pathology , Urinary Tract Infections/immunology , Urinary Tract Infections/pathology , Urothelium/microbiology , Urothelium/ultrastructureABSTRACT
Protopolystoma xenopodis and Protopolystoma orientalis are polystomatid monogeneans respectively specific to the parapatric anurans Xenopus laevis and Xenopus muelleri. Parasite larval stages may invade the kidneys of foreign Xenopus spp. but die before migration to the definitive urinary bladder site. Laboratory experiments to assess the effect of a primary incompatible kidney infection on a secondary compatible infection found: (1) a small, significant decrease in the survivorship of P. xenopodis kidney stages (23-37 days p.i. at 25 degrees C) in X. laevis laevis previously challenged with P. orientalis; (2) a significant effect of prior P. orientalis challenge on P. xenopodis development and establishment in the urinary bladder of X. laevis 100 days p.i. (at 21 degrees C); (3) no effect of prior P. xenopodis challenge on adult P. orientalis establishment in X. muelleri (at 21 degrees C), but a significant negative influence on reproductive output (days 0-50 post-patency). Partial cross-resistance to heterospecifics may therefore be induced by Protopolystoma spp. infections in the kidneys of an incompatible host, demonstrating that at least some elements of the host response are non-species specific. The effects observed were weak compared to the strong host resistance known to be generated by an established compatible primary infection with respect to conspecifics. This difference suggests that strong acquired resistance to Protopolystoma species is species-specific and/or induced only by older stages surviving in compatible hosts.
Subject(s)
Kidney Diseases/parasitology , Trematoda/physiology , Trematode Infections/parasitology , Xenopus laevis/parasitology , Xenopus/parasitology , Animals , Cloaca/parasitology , Cross Reactions , Host-Parasite Interactions , Kidney/parasitology , Kidney Diseases/immunology , Species Specificity , Trematoda/immunology , Trematode Infections/immunology , Urinary Bladder/parasitology , Urinary Bladder Diseases/immunology , Urinary Bladder Diseases/parasitologyABSTRACT
AIMS: To identify the amyloid protein in a patient with amyloidosis localised to the urinary bladder, and to see whether subtyping of the protein by sequence analysis increases the understanding of the selection of the urinary bladder as the site of amyloid deposition. METHODS: A patient with gross haematuria and a congophilic mass in his urinary bladder was evaluated further. Characterisation of the amyloid protein was performed using conventional histological and immunohistochemical methods. Determination of the N-terminal amino acid sequence of the amyloid protein was performed using protein sequencers. RESULTS: The patient's history, physical examination, and laboratory evaluation excluded the involvement of other organs, justifying a diagnosis of amyloidosis localised to the urinary bladder. Histological and immunological studies showed that the amyloid protein deposited in the urinary bladder of the patient was probably of the amyloid light chain type. No plasma cells or lymphocytes were seen in sections of the urinary bladder and lower ureter adjacent to the amyloid deposits. Molecular analysis showed the sequence NFMLTQPHSISGSPG, which assigned the amyloid protein to either the Vlambda(I) or the Vlambda(VI) immunoglobulin (Ig) light chain families. CONCLUSIONS: The findings suggest that the amyloid protein in this patient originated outside the urinary bladder. The heterogeneity of the Ig proteins in known cases of amyloidosis of the lower urinary tract suggests that the amino acid residues, which determine the Vlambda subtyping, have no major role in restricting the deposited protein to the urinary bladder.
Subject(s)
Amyloid/immunology , Amyloidosis/immunology , Immunoglobulin Light Chains/analysis , Urinary Bladder Diseases/immunology , Amino Acid Sequence , Amyloid/genetics , Amyloidosis/surgery , Electrophoresis, Polyacrylamide Gel , Hematuria/immunology , Humans , Immunoglobulin Light Chains/genetics , Male , Middle Aged , Molecular Sequence Data , Sequence Analysis, Protein , Urinary Bladder Diseases/surgeryABSTRACT
This study examined the hypothesis that the nature of the host cellular immune response to schistosome ova is a risk factor for urinary tract morbidity in areas in which Schistosoma haematobium is endemic. S. haematobium-infected children and adolescents with bladder pathology assessed by ultrasonography had 54-fold greater tumor necrosis factor (TNF)-alpha production and a 120-fold greater ratio of TNF-alpha to interleukin (IL)-10 release by peripheral blood mononuclear cells in response to egg antigens, in comparison with control children and adolescents matched by age, sex, and infection severity. Mycobacterial antigens also stimulated 7-fold more TNF-alpha among subjects with bladder morbidity than in control subjects, which suggests an innate predisposition to enhanced TNF-alpha production. Levels of egg antigen-induced IL-4 and -5 and interferon-gamma were equivalent in subjects with and without bladder pathology. Thus, children and adolescents predisposed to increased TNF-alpha production to S. haematobium infection are more likely to develop an exaggerated granulomatous response to ova trapped in the bladder wall, with associated urinary tract pathology.
Subject(s)
Interleukin-10/metabolism , Schistosoma haematobium/immunology , Schistosomiasis haematobia/immunology , Tumor Necrosis Factor-alpha/metabolism , Urinary Bladder Diseases/immunology , Adolescent , Animals , Antigens, Helminth/immunology , CD4-Positive T-Lymphocytes/immunology , Case-Control Studies , Child , Female , Humans , Male , Parasite Egg Count , Schistosoma haematobium/growth & development , Schistosomiasis haematobia/diagnostic imaging , Schistosomiasis haematobia/parasitology , Ultrasonography , Urinary Bladder/diagnostic imaging , Urinary Bladder Diseases/diagnostic imaging , Urinary Bladder Diseases/parasitologyABSTRACT
Combined surface radiation of renal projection area and intravascular laser radiation of blood (AZOR-2K unit) were used in combined treatment of 54 patients with urinary tuberculosis. Analysis of immunological and hematological indices of peripheral blood of patients before and after the combined treatment showed that low-intensity laser radiation activates local system of T-helpers which after specific antigenic impact differentiate into T-helpers-1. The latter synthesize in loco gamma-interferon, TNF-alpha and beta and IL-2 stimulating bactericidal mechanisms directed at destruction of M. tuberculosis and resolution of the infection focus.